Lisata Therapeutics Acquired by Kuva Labs at $4.00 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Source: Benzinga
- Acquisition Agreement: Lisata Therapeutics has agreed to be acquired by Kuva Labs at $4.00 per share in cash, reflecting an 85% premium that underscores strong investor interest in its pipeline.
- Contingent Value Rights: Lisata shareholders will receive two contingent value rights (CVRs) tied to future milestones, with one paying $1 per share upon the reversion of Greater China rights and another upon Kuva's filing of regulatory documents, enhancing the deal's potential value.
- Strong Financial Position: As of September 30, 2025, Lisata had approximately $19 million in cash and cash equivalents, which is expected to support operations into the first quarter of 2027 without any debt, ensuring financial stability.
- Drug Development Progress: Certepetide, an investigational cyclic peptide, has shown favorable safety and tolerability in pancreatic cancer trials and has received Fast Track and multiple Orphan Drug and Rare Pediatric Disease designations from U.S. and European regulators, bolstering its market prospects.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on LSTA
About LSTA
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Nathan’s Famous, Inc. (NASDAQ: NATH) for potential violations related to its sale to Smithfield Foods, Inc. for $102.00 per share in cash, aiming to protect shareholder rights and seek increased compensation.
- Transaction Details: Penumbra, Inc. (NYSE: PEN) is being sold for $374.00 in cash or 3.8721 shares of Boston Scientific common stock, with Halper Sadeh LLC potentially advocating for more information and compensation to ensure transaction transparency for shareholders.
- Legal Rights: RAPT Therapeutics, Inc. (NASDAQ: RAPT) is selling to GSK plc for $58.00 per share, and Halper Sadeh LLC encourages shareholders to reach out to understand their legal rights and options, ensuring their interests are safeguarded in the transaction.
- Shareholder Support: Lisata Therapeutics, Inc. (NASDAQ: LSTA) is being sold for $4.00 per share in cash plus two non-tradeable rights, with Halper Sadeh LLC offering contingent fee legal services to help shareholders secure their rightful interests in the potential transaction.
Continue Reading
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Compensation Investigation: Monteverde & Associates is investigating the acquisition of Penumbra, Inc. by Boston Scientific Corporation, where shareholders are expected to receive either $374 in cash or 3.8721 shares of Boston Scientific, highlighting a commitment to shareholder rights.
- RAPT Transaction Details: In the sale of RAPT Therapeutics, Inc. to GSK plc, shareholders are anticipated to receive $58 in cash per share, reflecting positive market expectations regarding the transaction's value.
- Nathan's Famous Acquisition: Nathan’s Famous, Inc. is set to receive $102 in cash per share from Smithfield Foods, indicating a direct financial benefit to shareholders from this acquisition.
- Lisata Transaction Terms: Lisata Therapeutics, Inc. shareholders will receive $4 in cash per share along with potential contingent value rights in the sale to Smithfield Foods, suggesting future revenue opportunities for investors.
Continue Reading